NCT01416194 - Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU) | Biotech Hunter

Enrollment

10,497

Participants

Timeline

Start Date

July 25, 2011

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG

Bazedoxifene

Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.

DRUG

Bisphosphonate

Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.

DRUG

Raloxifene

Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.